How multimodal treatment affects tumor cells in the blood of people with rectal cancer.
Official title: The Effect of Multimodal Treatment of Rectal Cancer on Circulating Tumor Cells: A Prospective, Observational Study
Run by The Institute of Molecular and Translational Medicine, Czech Republic · NCT07112937 · Data updated 2026-11-12
This study will see if multimodal treatment changes levels of circulating tumor cells in people with rectal cancer.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | The Institute of Molecular and Translational Medicine, Czech Republic Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Ostrava) |
| Status | Recruiting |
| Started | May 2, 2023 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2027 |
| Registry record updated | November 10, 2026 |
| Trial ID | NCT07112937 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with a diagnosis of rectal cancer who are undergoing multimodal treatment and can provide serial blood samples are ideal candidates.
✕Probably not a fit
Patients with other active cancers, those not receiving multimodal therapy, or those unable to attend the site for serial blood draws are unlikely to receive benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Researchers will prospectively collect peripheral blood samples from rectal cancer patients at predefined time points during their multimodal therapy to measure circulating tumor cells (CTCs). The observational protocol compares CTC counts in patients who receive neoadjuvant chemoradiotherapy with those who do not. No experimental treatments are assigned and clinical care follows standard practice while samples are analyzed to track changes over time. The study excludes patients with other active cancers and is conducted at University Hospital Ostrava in the Czech Republic.
Why it matters
Potential benefit: If successful, the findings could help doctors use CTC levels to monitor treatment response or inform future personalized care for rectal cancer patients.
How similar studies have gone: Previous colorectal cancer research has shown CTC counts can correlate with prognosis, but using CTC monitoring to guide rectal cancer treatment decisions remains experimental.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: rectal cancer - Exclusion Criteria: no other cancer \-
Where it's running
-
University Hospital Ostrava
Ostrava, Czechia Recruiting
Study contacts
- Study coordinator: Josef Srovnal, Associate professor, MD, PhD
- Email: josef.srovnal@upol.cz
- Phone: +420 585632137
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
NeoCSR-Omics: CAPOX and Serplulimab Before or After Short-Course RT in Locally Advanced Rectal Cancer
This trial tests whether giving CAPOX chemotherapy with the PD-1 blocker serplulimab before or after short-course radiotherapy helps people with locally advanced rectal cancer achieve complete clinical or pathological responses.
-
PPISR for low- to mid-rectal cancer with anus-sparing aim
This study tests whether Precision Partial Intersphincteric Resection can be safely used to remove certain rectal cancers while preserving the anus.
-
BT-001 plus pembrolizumab for localized pMMR rectal cancer
This early-phase trial tests whether adding the oncolytic virus BT-001 to pembrolizumab is safe and tolerable for adults with localized pMMR rectal cancer prior to definitive surgery.
-
Transanal vs Robotic Total Mesorectal Excision for Low Rectal Cancer
This study tests whether taTME or robot-assisted TME works better for low rectal cancer patients and whether one method leads to fewer complications or conversions.
-
Gynecological and sexual aftereffects following rectal cancer treatment
This work will test whether gynecological anatomical changes after rectal cancer treatment are linked to ongoing sexual problems in women aged 18–60 who are in remission.
-
Selective completion total mesorectal excision guided by intra-operative frozen pathology after local excision for low rectal cancer
This trial tests whether using an immediate frozen-pathology result after local excision to decide if a full total mesorectal excision is needed can keep cancer controlled for adults with low rectal cancer who had a near-complete or small residual response to preoperative chemoradiotherapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.